IDEAYA Biosciences, Inc. IDYA
27.40 USD -2.96 (-9.75%)
Regular-session close
27.40 0.00 0.00%
After hours · Nov 17, 4:33 PM ET
26.69 Day range 31.85
26.69 52-week range 42.68
- YTD
- -20.74%
- 1 year
- -17.82%
News
seekingalpha.com Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More I maintain a 'Strong Buy' on Ideaya Biosciences, Inc.: the darovasertib NDA submission is complete, while IDE849 offers multiple registrational opportunities. Darovasertib plus crizotinib targets…benzinga.com RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
seekingalpha.com IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's…
gurufocus.com IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid TumorsPR News
prnewswire.com IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's…benzinga.com Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39 Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $44 to $39.
benzinga.com Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66 Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $65 to $66.
benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.
benzinga.com Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.
benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.
benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $60 to $63.
benzinga.com IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.18) by 4.27 percent. This is a 191.73 percent decrease over earnings…
benzinga.com IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and…
